These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
667 related articles for article (PubMed ID: 9751634)
1. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634 [TBL] [Abstract][Full Text] [Related]
2. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Rosen J; He M; Umbricht C; Alexander HR; Dackiw AP; Zeiger MA; Libutti SK Surgery; 2005 Dec; 138(6):1050-6; discussion 1056-7. PubMed ID: 16360390 [TBL] [Abstract][Full Text] [Related]
3. Galectin-3 is a presurgical marker of human thyroid carcinoma. Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965 [TBL] [Abstract][Full Text] [Related]
4. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421 [TBL] [Abstract][Full Text] [Related]
5. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors. Raphael SJ; McKeown-Eyssen G; Asa SL Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169 [TBL] [Abstract][Full Text] [Related]